Table 3 Grade ≥ 3 AEs regardless of attribution to navoximod
|  | Navoximod 50 mg BID (n = 1) | Navoximod 100 mg BID (n = 3) | Navoximod 200 mg BID (n = 3) | Navoximod 400 mg BID (n = 3) | Navoximod 600 mg BID (n = 3) | Navoximod 800 mg BID (n = 6) | All Patients 21/28 day schedule (N = 19) | Navoximod continuous schedule 600 mg BID (n = 3) | All Patients (N = 22) |
|---|---|---|---|---|---|---|---|---|---|
Any adverse event | 1 (100%) | 3 (100%) | 1 (33%) | 3 (100%) | 2 (67%) | 2 (33%) | 12 (63%) | 2 (67%) | 14 (63%) |
Neoplasm progression | – | – | 1 (33%) | 1 (33%) | 1 (33%) | – | 3 (16%) | – | 3 (14%) |
AST increased | – | – | 1 (33%) | 1 (33%) |  | – | 2 (11%) | – | 2 (9%) |
Anemia | – | – | – | – | 1 (33%) | – | 1 (5%) | – | 1 (5%) |
Ascites | – | – | – | – | 1 (33%) | – | 1 (5%) | – | 1 (5%) |
Dysphagia | 1 (33%) | – | – | – |  | – | 1 (5%) | – | 1 (5%) |
Hypokalemia | – | – | – | – |  | 1 (17%) | 1 (5%) | – | 1 (5%) |
Hypotension | – | – | – | – |  | 1 (17%) | 1 (5%) | – | 1 (5%) |
Lower GI hemorrhage | – | – | – | – |  | 1 (17%) | 1 (5%) | – | 1 (5%) |
Mental status changes | – | – | – | 1 (33%) |  | – | 1 (5%) | – | 1 (5%) |
Muscular weakness | – | – | – | – | 1 (33%) | – | 1 (5%) | – | 1 (5%) |
Peripheral neuropathy | – | – | – | 1 (33%) | – | – | 1 (5%) | – | 1 (5%) |
Acute pancreatitis | – | 1 (33%) | – | – | – | – | 1 (5%) | – | 1 (5%) |
Pneumonia | – | 1 (33%) | – | – | – | – | 1 (5%) | – | 1 (5%) |
Small Intestinal Obstruction | – | 1 (33%) | – | – | – | – | 1 (5%) | – | 1 (5%) |
Tumor pain | – | – | – | – | 1 (33%) | – | 1 (5%) | – | 1 (5%) |
Bloody discharge | – | – | – | – | – | – | – | 1 (33%) | 1 (5%) |
Diverticulitis | – | – | – | – | – | – | – | 1 (33%) | 1 (5%) |
Lymphopenia | – | – | – | – | – | – | – | 1 (33%) | 1 (5%) |